Exploring potential anti-inflammatory effects of medicinal cannabis
Abstract
Purpose
Inflammation is thought to play a key role in malignant disease and may play a significant part in the expression of cancer-related symptoms. Cannabidiol (CBD) is a bioactive compound in cannabis and is reported to have significant anti-inflammatory properties.
Method
Serial C-reactive protein (CRP) levels were measured in all participants recruited to a randomised controlled trial of CBD versus placebo in patients with symptoms related to advanced cancer. A panel of inflammatory cytokines was measured over time in a subset of these patients.
Results
There was no difference between the two arms in the trajectory of CRP or cytokine levels from baseline to day 28.
Conclusion
We were unable to demonstrate an anti-inflammatory effect of CBD in cancer patients.
Trial registration
ANZCTR 26180001220257, registered 20/07/2018.
This library aims to empower you with knowledge but it does not replace the personalized advice and guidance a healthcare professional can provide. Before implementing any changes to your health regimen based on the contents of this library, we strongly advise you to consult with a qualified healthcare professional. Your doctor’s expertise is essential for interpreting how these insights may apply to your unique health circumstances.